LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Accueil・Liste d'Actions・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Fermé

SecteurSoins de santé

54.89 0.96

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

54.31

Max

55.05

Chiffres clés
By Trading Economics
Revenu	1.6B 2.7B
Ventes	-1B 11B
P/E Moyenne du Secteur	15.392 49.888
BPA	1.31
Rendement du dividende	4.37
Marge bénéficiaire	23.309
Employés	32,500
EBITDA	1.5B 3.7B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+16.25% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	4.37% 2.38%
Prochains Résultats	30 juil. 2026
Date du Prochain Dividende	31 juil. 2026
Date du Prochain Détachement de Dividende	2 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-5.8B 112B
Ouverture précédente	53.93
Clôture précédente	54.89

Bristol-Myers Squibb Co. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juin 2026, 13:08 UTC

Résultats

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

12 mai 2026, 06:42 UTC

Principaux Mouvements du Marché

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30 avr. 2026, 11:14 UTC

Résultats

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

29 mai 2026, 08:15 UTC

Market Talk

Résultats

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

5 mai 2026, 18:12 UTC

Résultats

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mai 2026, 13:54 UTC

Résultats

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 avr. 2026, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 avr. 2026, 14:13 UTC

Résultats

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 avr. 2026, 12:57 UTC

Résultats

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 avr. 2026, 11:19 UTC

Résultats

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 avr. 2026, 10:34 UTC

Résultats

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 avr. 2026, 21:23 UTC

Résultats

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Comparaison

Variation de prix

Bristol-Myers Squibb Co. prévision

Objectif de Prix

By TipRanks

16.25% hausse

Prévisions sur 12 Mois

Moyen 63.31 USD 16.25%

Haut 75 USD

Bas 40 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

20 ratings

Achat

Maintien

Vente

Basé sur 20 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.